Depression is one of the most common and serious mental health conditions in the world. Doctors call the most severe form major depressive disorder, or MDD.
People with this condition often experience long periods of sadness, loss of interest in daily life, sleep problems, low energy, and difficulty concentrating. Depression can affect work, relationships, and physical health. According to global health estimates, depression is one of the leading causes of disability worldwide.
Although many people benefit from antidepressant medications, these treatments do not work for everyone. In fact, about three out of ten people with major depression develop what doctors call treatment‑resistant depression, often shortened to TRD.
This means their symptoms do not improve enough even after trying several standard antidepressant drugs. For these patients, finding effective treatment can be extremely challenging.
In recent years, a drug called ketamine has attracted attention because it can reduce depressive symptoms very quickly. Unlike traditional antidepressants, which may take weeks to work, ketamine can sometimes improve mood within hours or days.
Because of this rapid effect, ketamine has become an important option for people with treatment‑resistant depression. However, despite its growing use, scientists have not fully understood exactly how ketamine works inside the human brain.
Understanding the biological mechanism behind ketamine’s antidepressant effects is important. If researchers know how the drug works, they may be able to design safer treatments, identify which patients will benefit the most, and develop new medicines that work in similar ways.
A new study from researchers in Japan has taken an important step toward solving this mystery. The research was led by Professor Takuya Takahashi at the Department of Physiology at Yokohama City University Graduate School of Medicine. The findings were published on March 5, 2026, in the scientific journal Molecular Psychiatry.
The research team used a sophisticated brain imaging method called positron emission tomography, often known as PET scanning. PET scans allow scientists to observe certain biological processes inside the living brain. By using special chemical tracers, researchers can track the activity of specific proteins or receptors that help brain cells communicate.
The scientists focused on a particular brain receptor called the AMPA receptor, formally known as the glutamate α‑amino‑3‑hydroxy‑5‑methyl‑4‑isoxazole propionic acid receptor.
This receptor plays an important role in how brain cells send signals to each other. It is also involved in synaptic plasticity, which is the brain’s ability to adapt, learn, and form new connections.
Previous studies in animals suggested that ketamine might work by influencing these AMPA receptors. However, until now, researchers had not been able to directly observe these changes in the living human brain.
To solve this problem, Professor Takahashi’s team developed a special PET tracer called [¹¹C]K‑2. This tracer attaches to AMPA receptors and allows them to be seen during brain scans. With this technology, scientists could observe how ketamine affects these receptors in real time.
The study combined data from three clinical trials conducted in Japan. The research involved 34 patients with treatment‑resistant depression and 49 healthy participants who served as a comparison group. The patients received either intravenous ketamine or a placebo treatment over a two‑week period.
Brain scans were performed before the treatment began and again after the final infusion. By comparing the scans, the researchers could see how the levels and distribution of AMPA receptors changed in different parts of the brain.
The results revealed clear differences between people with treatment‑resistant depression and healthy individuals. Patients with depression showed abnormal levels of AMPA receptors in several brain regions. These changes were not spread evenly across the brain but appeared in specific areas linked to mood and emotional processing.
When patients received ketamine, the researchers observed important changes in these receptors. The effects were not uniform across the brain. Instead, certain brain regions showed increases in receptor levels, while others showed decreases.
For example, changes were observed in cortical areas involved in thinking and emotional regulation. At the same time, reductions appeared in a region called the habenula, which is known to play a role in reward processing and negative mood states.
Importantly, these changes in AMPA receptors were strongly connected with improvements in patients’ depressive symptoms. In other words, the brain areas that showed the most receptor changes were often the same areas linked to clinical improvement.
This provides the first direct evidence in humans that ketamine’s antidepressant effects involve changes in AMPA receptor activity. The findings also confirm earlier results from animal experiments, helping bridge the gap between laboratory research and real patient treatment.
Another important outcome of the study is the possibility of developing a biological marker, or biomarker, for treatment response. A biomarker is a measurable biological signal that can help doctors predict how a patient will respond to a treatment.
The researchers suggest that PET imaging of AMPA receptors could eventually help identify which patients with treatment‑resistant depression are most likely to benefit from ketamine therapy.
From a scientific perspective, this research is significant because it moves beyond theoretical explanations and provides direct imaging evidence in humans. The use of the new PET tracer allowed scientists to observe real‑time changes in brain receptor activity, something that was not previously possible.
However, the study also has limitations. The number of patients involved was relatively small, and PET scanning is an expensive and complex technology that may not be widely available in routine clinical practice. Larger studies will be needed to confirm these findings and determine how they can be applied in everyday psychiatric care.
Even with these limitations, the research offers valuable insights into the biology of depression and the mechanism of ketamine treatment. By identifying AMPA receptor changes as a key part of ketamine’s antidepressant action, scientists now have a clearer target for developing future therapies.
Overall, the study represents an important step toward more personalized treatment for depression. If doctors can eventually predict which patients will respond to ketamine based on brain imaging, treatment could become faster, more precise, and more effective.
For people struggling with treatment‑resistant depression, advances like this could bring new hope for relief and recovery.
If you care about health, please read studies that scientists find a core feature of depression and this metal in the brain strongly linked to depression.
For more health information, please see recent studies about drug for mental health that may harm the brain, and results showing this therapy more effective than ketamine in treating severe depression.
Copyright © 2026 Knowridge Science Report. All rights reserved.
